Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.38 CAD
Change Today 0.00 / 0.00%
Volume 224.3K
MBX On Other Exchanges
Symbol
Exchange
Toronto
OTC US
Frankfurt
As of 2:47 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

microbix biosystems inc (MBX) Snapshot

Open
C$0.39
Previous Close
C$0.38
Day High
C$0.40
Day Low
C$0.36
52 Week High
11/20/14 - C$0.90
52 Week Low
07/30/15 - C$0.36
Market Cap
31.6M
Average Volume 10 Days
76.5K
EPS TTM
C$-0.0019
Shares Outstanding
83.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MICROBIX BIOSYSTEMS INC (MBX)

Related News

No related news articles were found.

microbix biosystems inc (MBX) Related Businessweek News

No Related Businessweek News Found

microbix biosystems inc (MBX) Details

Microbix Biosystems Inc. develops, manufactures, and sells biological products and technologies in North America, Europe, and internationally. The company manufactures and sells cell culture-based biological products, as well as infectious disease antigens. It offers infectious disease antigens, such as viral, bacterial, and parasitic products used in various applications, including immunodiagnostic assays; basic and applied research in virology, microbiology, cell biology, molecular biology, immunology, and pathology; as controls and calibrators for a range of medical devices; and for vaccine and antiviral research and development. In addition, the company provides adenovirus vectors, cells, and services to biopharmaceutical and biotechnology researchers and companies, as well as provides facility, technical, and production personnel for contract research and development. Its pipeline of technologies and products includes LumiSort semen sexing technology for the livestock industries; Kinlytic, a thrombolytic drug with various approved and potential applications, including the treatment of life-threatening blood clots, and VIRUSMAX, a proprietary technology for increasing virus yields in the manufacture of influenza vaccine. The company offers products for human health applications, namely in the vaccine, therapeutic, and diagnostic markets, as well as animal reproductive markets. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

Founded in 1988

microbix biosystems inc (MBX) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: C$217.0K
Founder, Executive Chairman, Member of Audit ...
Total Annual Compensation: C$190.9K
Chief Financial Officer
Total Annual Compensation: C$190.8K
Senior Vice President of Sales & Business Dev...
Total Annual Compensation: C$174.8K
Vice President of Biopharmaceuticals
Total Annual Compensation: C$150.7K
Compensation as of Fiscal Year 2014.

microbix biosystems inc (MBX) Key Developments

Microbix Biosystems Inc. Introduces Two New Toxoplasma Gondii Products

Microbix Biosystems Inc. announced the commercial introduction of two new Toxoplasma Gondii products targeted at immunoassay manufacturers looking for improved sensitivity and specificity of diagnostic tests. Toxoplasma is a common parasitic infection spread primarily by cats and contaminated food. While toxoplasma infection is usually asymptomatic in healthy people, it can cause serious complications to a developing fetus and to the immune compromised (e.g. HIV infected patients). Toxoplasma testing is part of the TORCH diagnostic panel (Toxoplasma, Rubella, CMV, Herpes) routinely administered to expectant mothers in the first trimester of pregnancy. The new antigens available from Microbix will be used in IgG and IgM antibody detection tests produced by most of the diagnostic manufacturers. Many of these companies already use antigens produced by Microbix.

Microbix Biosystems Inc. Presents at 5th LD Micro Invitational Conference, Jun-03-2015 08:00 AM

Microbix Biosystems Inc. Presents at 5th LD Micro Invitational Conference, Jun-03-2015 08:00 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049, United States. Speakers: Vaughn C. Embro-Pantalony, Chief Executive Officer, President, Director, Member of Audit Committee and Member of Human Resources, Compensation & Governance Committee.

Microbix Biosystems Inc. Reports Financial Results for the Second Quarter and Six Months Ended March 31, 2015

Microbix Biosystems Inc. reported financial results for the second quarter and six months ended March 31, 2015. For the quarter, the company reported total revenue of $2,544,900 compared to $2,073,097 in the second quarter last year, or an increase of 23%. Total revenue was made up entirely of Virology products as there was no R & D Contract revenue in the quarter. This improvement was mainly attributable to increased sales of the company's core antigen products. To a lesser extent, sales were positively impacted by the net effects of foreign currency fluctuations versus the Canadian dollar year over year, and the initial sale of the Company's new molecular diagnostic products. Operating income was $86,335 compared to $269,620 in the second quarter of 2014. The lower operating income was the result of increased operating expenses to support the VIRUSMAX litigation during the quarter. Cash generated from operations was $496,135 compared to cash used in operations of $312,696 in the same period last year, primarily due to improved management of working capital compared to the prior year (lower accounts receivable and higher accounts payable). Cash used in investing activities was $2,172,645 in the second quarter compared to $613,245 in the same period last year, primarily due to development of the LumiSort prototype instrument. As a result, net cash inflow was $325,506 compared to $941,391 in the second quarter of last year. For the six months, the company reported total revenue of $4,540,733 compared to $4,000,982 for the same period in 2014, or an increase of 14%. Virology products revenue was $4,421,331 in the first six months compared to $3,812,613 in the same period last year, or an increase of 16%. Strong customer demand accounted for the majority of this increase, in addition to a favorable foreign currency impact. Operating income was $176,888 compared to $484,026 in the first six months of last year. The lower operating income is the result of increased operating expenses to support the VIRUSMAX litigation, which more than offset the impact of higher revenues in the first six months of 2014 compared to the same period last year. Cash generated from operations was $691,341 compared to cash used in operations of $404,149 in the first six months 2014. Cash used in investing activities was $3,332,951 compared to $699,642 in the first six months of last year. The increase was largely due to the investment in the LumiSort prototype in the first six months of 2015. Net cash inflow was $569,543 compared to $889,619 in the same period last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MBX:CN C$0.38 CAD 0.00

MBX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MBX.
View Industry Companies
 

Industry Analysis

MBX

Industry Average

Valuation MBX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.3x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MICROBIX BIOSYSTEMS INC, please visit www.microbix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.